Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response.
Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats.
Cell Source is currently commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia).
Pending clinical trials aspire to show dramatic improvements in the treatment of lymphoma and leukemia.
Please see this link for an informative video presentation by Cell Source CEO Itamar Shimrat: http://youtu.be/0CoGVvv-AXk